Nov 6, 2017Anavex Life Sciences presenting at Society for Neuroscience Nov. 11-15, 2017 in Washington DCEfficacy of ANAVEX 2-73, a Sigma-1 receptor agonist, in the MECP2 mouse model of Rett syndrome
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
